Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life

C J Malkin, P J Pugh, P D Morris, K E Kerry, R D Jones, T H Jones, K S Channer

Background: Low serum testosterone is associated with several cardiovascular risk factors including dyslipidaemia, adverse clotting profiles, obesity, and insulin resistance. Testosterone has been reported to improve symptoms of angina and delay time to ischaemic threshold in unselected men with coronary disease.

Objective: This randomised single blind placebo controlled crossover study compared testosterone replacement therapy (Sustanon 100) with placebo in 10 men with ischaemic heart disease and hypogonadism.

Results: Baseline total testosterone and bioavailable testosterone were respectively 4.2 (0.5) nmol/l and 1.7 (0.4) nmol/l. After a month of testosterone, delta value analysis between testosterone and placebo phase showed that mean (SD) trough testosterone concentrations increased significantly by 4.8 (6.6) nmol/l (total testosterone) (p = 0.05) and 3.8 (4.5) nmol/l (bioavailable testosterone) (p = 0.025), time to 1 mm ST segment depression assessed by Bruce protocol exercise treadmill testing increased by 74 (54) seconds (p = 0.002), and mood scores assessed with validated questionnaires all improved. Compared with placebo, testosterone therapy was also associated with a significant reduction of total cholesterol and serum tumour necrosis factor α with delta values of −0.41 (0.54) mmol/l (p = 0.04) and −1.8 (2.4) pg/ml (p = 0.05) respectively.

Conclusion: Testosterone replacement therapy in hypogonadal men delays time to ischaemia, improves mood, and is associated with potentially beneficial reductions of total cholesterol and serum tumour necrosis factor α.

METHODS

Summary of protocol

This was a randomised, single blind crossover study of testosterone replacement therapy versus placebo in men with hypogonadism and coronary heart disease. Men who had never had an exercise test were required to perform a run-in exercise test according to the standard Bruce protocol. Participants were randomly assigned to testosterone injections (1 ml of Sustanon 100, 100 mg testosterone/ml) every two weeks or placebo for one month. Drug order was allocated by blocks of computer generated random numbers. Before and after the month of treatment, patients were assessed in the cardiology department with questionnaires, blood tests, and a treadmill exercise test. After the initial month of treatment there was a month washout period of no treatment, after which the patient crossed over to the alternate arm of treatment. At the end of the three month study period, patients continued taking testosterone as prescribed by their own doctor.

Abbreviations: ELISA, enzyme linked immunosorbent assay; HDL, high density lipoprotein; LDL, low density lipoprotein; PSA, prostate specific antigen; TNFα, tumour necrosis factor α.
Participants

Twelve men with coronary artery disease (> 70% stenosis of a major coronary artery at coronary angiography) or previous proven myocardial infarction with typical symptoms of angina pectoris were recruited from August 2002 to December 2002. These patients were referred from a male andrology clinic and each had a clinical need for testosterone replacement as judged by a consultant endocrinologist (THJ). All patients were naive to androgen replacement and their androgen status had never been investigated. All patients gave informed written consent and the local ethics committee approved the protocol. No changes were made to antianginal medication for four weeks before or during the trial. Inclusion criteria for patients were male sex, age greater than 18 years, and a clinical indication for testosterone therapy. Patients were excluded if they had a prostate specific antigen (PSA) concentration above the normal range or any other contraindication to androgen therapy. They were also excluded if they had left main stem (or equivalent) stenosis, a coronary or cerebrovascular event or other trial drugs within the preceding three months, severe hypertension (blood pressure > 180/114 mm Hg), significant arrhythmia, poor physical mobility, and ECG abnormalities precluding ST segment analysis on a treadmill.

Of 12 patients screened, one patient did not meet accepted ECG criteria during exercise treadmill testing and 11 were randomly assigned to treatment. One study patient underwent an elective coronary artery bypass earlier than expected and was withdrawn from the study. Complete data were available for 10 patients; Table 1 presents baseline data.

Drug

We used intramuscular injection of Sustanon 100 every two weeks, which is the usual method of initiating testosterone treatment in men with hyponadism. Testosterone (Sustanon 100, 100 mg testosterone/ml; Organon Laboratories Ltd, Cambridge, UK) or placebo (1 ml of 0.9% normal saline) in an identical syringe was given by deep intramuscular injection to the buttock every two weeks by a member of the research staff. Patients were blinded to the identity of the injection and the drug was drawn up away from the patient.

Table 1

<table>
<thead>
<tr>
<th>Patient characteristic</th>
<th>Mean (SD) or n</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>60.8 (4.6)</td>
<td></td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>31.3 (2.87)</td>
<td></td>
</tr>
<tr>
<td>Total testosterone (nmol/l)</td>
<td>4.2 (0.5)</td>
<td>&gt;7.5</td>
</tr>
<tr>
<td>Bioavailable testosterone (nmol/l)</td>
<td>1.7 (0.4)</td>
<td>&gt;2.5</td>
</tr>
<tr>
<td>Follicle stimulating hormone (nmol/l)</td>
<td>6.6 (3.6)</td>
<td>1.1–13.3</td>
</tr>
<tr>
<td>Luteinising hormone (nmol/l)</td>
<td>4.5 (3.5)</td>
<td>1.4–9.2</td>
</tr>
<tr>
<td>Prostate specific antigen (µg/l)</td>
<td>1.01 (1.3)</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Angiographically proven coronary disease</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Previous myocardial infarction</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>27</td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>Clidapidegrel</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>ACE or ARB</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>β1 Blocker</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Calcium channel antagonist</td>
<td>71</td>
<td></td>
</tr>
<tr>
<td>HMG-CoA reductase inhibitor</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Oral nitrate</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Previous CABG</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Previous angiotensin</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

Table 2

<table>
<thead>
<tr>
<th>Variable</th>
<th>Placebo Baseline</th>
<th>4 weeks</th>
<th>p Value</th>
<th>Analysis of difference between groups</th>
<th>Placebo Testosterone</th>
<th>4 weeks p Value</th>
<th>p Value</th>
<th>Difference with testosterone 95% CI p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time to 1 mm ST depression (s)</td>
<td>318 (99)</td>
<td>399 (84)</td>
<td>0.0001</td>
<td>74 (54)</td>
<td>35.4 to 112.6</td>
<td>0.002*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum TNF (pg/ml)</td>
<td>2.39 (1.1)</td>
<td>3.44 (2.3)</td>
<td>0.267</td>
<td>4.13 (2.8)</td>
<td>2.9 (1.8)</td>
<td>0.007</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemoglobin (g/l)</td>
<td>147 (8.6)</td>
<td>150 (8.9)</td>
<td>0.001</td>
<td>147 (9.8)</td>
<td>150 (8.6)</td>
<td>0.008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Packed cell volume</td>
<td>0.44 (0.027)</td>
<td>0.44 (0.027)</td>
<td>0.278</td>
<td>0.44 (0.027)</td>
<td>0.44 (0.027)</td>
<td>0.273</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>4.19 (0.59)</td>
<td>3.92 (0.55)</td>
<td>0.038</td>
<td>4.19 (0.59)</td>
<td>3.92 (0.55)</td>
<td>0.008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDL (mmol/l)</td>
<td>2.1 (0.6)</td>
<td>2.01 (0.6)</td>
<td>0.001</td>
<td>2.1 (0.6)</td>
<td>2.01 (0.6)</td>
<td>0.008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDL (mmol/l)</td>
<td>0.95 (0.23)</td>
<td>0.9 (0.17)</td>
<td>0.007</td>
<td>0.94 (0.23)</td>
<td>0.9 (0.17)</td>
<td>0.008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triglyceride (mmol/l)</td>
<td>2.87 (1.94)</td>
<td>2.91 (1.8)</td>
<td>0.001</td>
<td>2.87 (1.94)</td>
<td>2.91 (1.8)</td>
<td>0.008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total testosterone (nmol/l)</td>
<td>5.55 (2.36)</td>
<td>5.5 (2.53)</td>
<td>0.001</td>
<td>5.55 (2.36)</td>
<td>5.5 (2.53)</td>
<td>0.008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bioavailable testosterone (nmol/l)</td>
<td>3.63 (1.8)</td>
<td>3.5 (1.7)</td>
<td>0.008</td>
<td>3.63 (1.8)</td>
<td>3.5 (1.7)</td>
<td>0.008</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; HMG-CoA, hydroxymethyl glutaryl coenzyme A.
Patient assessment

Patients were assessed at weeks 0, 4, 8, and 12 between 8 am and 9.30 am under fasting conditions and within 10–14 days of the final injection of that phase. Demographic details, hormone profiles, PSA concentration, and antianginal drug use were recorded at the beginning of the trial. Treadmill exercise testing was performed at weeks 0, 4, 8, and 12 according to the Bruce protocol (MAX-1 Marquette advanced exercise system, software version 002E). Patients continued their medication but were asked not to use glyceryl trinitrate for six hours before the test. The primary end point was defined as the time to 1 mm ST segment depression and exercise tests were terminated when this criterion was met. All treadmill tests were supervised by a cardiac technician with one investigator (CJM) present.

Electrocardiographic data were analysed by the Marquette 002E software package. This system analyses the signal averaged ECG and produces a graphical display of the level of the ST segment 80 ms after the J point against time. Time to 1 mm ST segment depression was measured from computer derived analysis effectively eliminating observer bias. All blood tests were performed at weeks 0, 4, 8, and 12; total testosterone and sex hormone binding globulin were measured by enzyme immunoassay (DRG Instruments GmbH, Marburg, Germany). Bioavailable testosterone was calculated by a modification of the method described by Tremblay and Dube. In this method testosterone is removed from the test serum by the addition of activated charcoal and replaced by testosterone labelled with hydrogen-3, which binds to sex hormone binding globulin and other plasma proteins in equimolar concentrations as native testosterone. Sex hormone binding globulin-bound testosterone is then precipitated out of the sample by the addition of cold albumen, is then measured by an enzyme immunoassay counter. Full blood count, glucose concentration, and lipid profiles were measured with standard hospital assays. Low density lipoprotein (LDL) cholesterol was calculated with the Friedewald equation ((LDL cholesterol = total cholesterol – (high density lipoprotein + triglyceride / 2.2)). Serum tumour necrosis factor α (TNFα) was assayed with high sensitivity enzyme linked immunosorbent assay (ELISA) (Quantikine R&D, Abingdon, UK). PSA was measured at the beginning and end of the trial.

Patients were asked to complete the Seattle angina questionnaire (an objective measure of quality of life in patients with angina), the Beck depression inventory (a commonly used assessment of mood and depressive symptoms), the general health screening questionnaire (a multipurpose mood and general wellbeing screening tool), and the androgen deficiency in the adult male screening questionnaire at weeks 0, 4, 8, and 12. The androgen screening questionnaire is a 10 statement true or false answer sheet. A positive screen is defined as a score of 3 or more out of 10 or a single positive response to any one of two highly specific questions: “Do you have reduced libido (sex drive)?” or “Do you have reduced ability to maintain erections?”

Statistical analysis and sample size calculation

From previous work with eugonadal men, in which we found a 37% increase in time to 1 mm ST segment depression with testosterone, we calculated that for hypogonadal men 12 participants would be needed to detect a 50% increase in a crossover study protocol, with 80% power and 5% significance.

The raw data were analysed with a statistical software package (SPSS version 11.5, SPSS Inc, Chicago, Illinois, USA). The data were tested against a normal distribution with Kolmogorov-Smirnov tests. All the biological data were found to be normally distributed and therefore were tested with paired t tests. Questionnaire scores were compared by Wilcoxon matched pair tests. The baseline results of each crossover phase were examined and tested for period or treatment period interaction. When no such interaction was found data were deemed suitable for further analysis. Unless otherwise stated, data are expressed as mean (SD). Significance was accepted when p < 0.05.

RESULTS

Ten patients completed the study. Table 2 summarises the results. Testosterone treatment induced a rise in serum testosterone, whereas placebo had no significant effect. The time to 1 mm ST segment depression increased by 81 (48) seconds in the testosterone phase compared with an increase of 7.2 (32) seconds in the placebo phase (fig 1). The mean difference in exercise time between testosterone therapy and placebo was 74 (54) seconds (95% confidence interval (CI) 35.4 to 112.6 seconds). Compared with placebo, testosterone therapy also induced small but significant rises in haemoglobin and packed cell volume but reductions in serum TNFα and total cholesterol (fig 2).

As expected serum PSA measured at screening and at the end of the trial rose slightly (from 1.01 (1.3) to 1.10 (1.4) µg/l, p = 0.03); however, there were no new symptoms of prostatic outflow obstruction and the final concentration of PSA remained well within the age adjusted normal range (< 4.5 µg/l). No other adverse effects were reported.

Testosterone treatment was also associated with significant improvement in mood, as assessed by questionnaire (table 3). Compared with placebo there were reductions in Beck depression inventory scores, general health screening score, and androgen deficiency screening scores (fig 3). There was a trend to reduction of the Seattle angina questionnaire score, but this did not reach significance.

DISCUSSION

Effect on myocardial ischaemia

In this study we have shown that one month of intramuscular testosterone replacement given to men with low basal testosterone and hypogonadism significantly improved time to ischaemic threshold compared with placebo. The absolute increase in time to ischaemia was about equivalent to half of one stage on a standard Bruce exercise protocol. This finding is in agreement with reports from several centres of an anti-ischaemic effect of testosterone. The fact that such a significant improvement in exercise time was seen with only one month of treatment suggests a rapid mode of action. Testosterone has been shown in numerous studies to be a vasodilator and we presume this to be the basis of its
anti-ischaemic action. This is the first study to examine exclusively hypogonadal men, although in our previous study of eugonadal men we did find a significant negative correlation between basal testosterone and increase in ischaemic threshold. The greater benefit seen in this present study of a hypogonadal cohort confirms the dose response effect that we found in our earlier study.

Effect on cholesterol
Testosterone therapy induced a reduction in serum total cholesterol, with no other significant effects seen on other lipid profiles. The effects of testosterone on lipid profiles are controversial. Most studies report that testosterone therapy causes reductions in HDL cholesterol, although this effect is absent or less apparent in elderly, hypogonadal, or obese men. Despite some conflicting data, in most studies testosterone effects modest reductions of total and LDL cholesterol. We found a similar reduction in total cholesterol in the present study even though all patients were treated with a statin. The reduction in LDL cholesterol was not significant and no reduction was seen in HDL cholesterol, which may be due to effects on insulin sensitivity. Testosterone therapy is reported to improve insulin resistance and components of the metabolic syndrome in obese men and in men with low testosterone. Given that in our cohort all were hypogonadal, 50% were diabetic, and the mean body mass index was 31.3 kg/m² it is possible that a positive effect on features of the insulin resistance syndrome attenuated the expected reduction in HDL cholesterol (reviewed in reference 28).

Effects on TNFα
TNFα is a pro-inflammatory cytokine and is increased in infective and inflammatory diseases. Atherosclerosis is acknowledged to be a disease of chronic inflammation. TNFα is both a marker and a mediator of atherosclerotic plaque development and complications. Serum TNFα is greatly increased during acute coronary syndromes but is also increased to a lesser degree in stable chronic angina and is a marker of future events. In this study we have shown that testosterone induces a small but significant reduction of TNFα compared with placebo. This is an intriguing finding, since there is considerable evidence from laboratory and clinical studies that testosterone has immune modulating effects. The reduced frequency of autoimmune disease in men compared with women has been attributed to the anti-inflammatory effect of androgens compared with oestrogens. There are several case reports and randomised controlled trials of androgen therapy in patients with inflammatory disease such as rheumatoid arthritis or systemic lupus erythematosus in which androgens have been found to improve clinical status and reduce inflammatory markers. In cell culture studies testosterone has been found to reduce the expression of pro-inflammatory cytokines such as TNFα, interleukin 1, and interleukin 6 in human vascular endothelium, monocytes, and fibroblasts. In live mice, gonadectomy and injection of bacterial endotoxin resulted in increased TNF production, which was

A reductase inhibitors. In postmenopausal women, for example, the administration of statin and hormone replacement is associated with greater cholesterol reduction than with statin alone.

Table 3: Questionnaire data (Wilcoxon matched pairs tests)

<table>
<thead>
<tr>
<th>Questionnaire</th>
<th>Placebo</th>
<th>Testosterone</th>
<th>Analysis of difference with testosterone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline 4 weeks</td>
<td>p Value</td>
<td>Baseline 4 weeks</td>
</tr>
<tr>
<td>Seattle angina score</td>
<td>42 (14) 45 (16.6) 0.35</td>
<td>44 (13.8) 40 (11.1) 0.075</td>
<td>–3.7 (5.9) 0.14</td>
</tr>
<tr>
<td>BDI</td>
<td>7 (4.7) 7 (4.8) 0.83</td>
<td>9 (6) 4 (4.2) 0.012*</td>
<td>–4.8 (6.1) 0.007*</td>
</tr>
<tr>
<td>GHQ</td>
<td>10.5 (5.9) 12 (3.7) 0.3</td>
<td>12 (4.1) 8.6 (2.5) 0.017*</td>
<td>–3.1 (2.9) 0.075</td>
</tr>
<tr>
<td>ADAM (1/10)</td>
<td>6 (2.4) 6 (2.2) 0.5</td>
<td>7 (2.0) 4 (2.3) 0.007*</td>
<td>–3.1 (3.3) 0.015*</td>
</tr>
</tbody>
</table>

* p < 0.05
ADAM, androgen deficiency in the adult male screen score; BDI, Beck depression inventory; GHQ, general health screen questionnaire.
reduced by hormone replacement. In castrated or sham castrated mice subjected to trauma haemorrhage, the macrophages from castrated animals produced more interleukin 1 and interleukin 6 than those from controls. There have been very few human studies, but elderly men with hypogonadism induced by gonadotrophin releasing hormone agonists developed a significant increase in serum TNFα and interleukin 6 compared with baseline. Hormone replacement in this group did reduce cytokine concentrations but failed to reach acceptable levels of significance. Yesilova and colleagues examined hypogonadal men with delayed puberty and found increased levels of immune activation that were reversed with androgen stimulating therapy. The present study therefore adds to the accumulating evidence that testosterone may have a beneficial anti-inflammatory action.

Limitations
The patients in this study did not present with symptoms of androgen deficiency; they were found to be hypogonadal during a cross sectional observational study. There may be a considerable number of men for whom testosterone therapy may be indicated, since men with coronary heart disease have lower testosterone concentrations than men with normal coronary angiograms and nearly a quarter of men with coronary disease are biochemically androgen deficient. Although a positive effect on inducible myocardial ischaemia was recorded we could not confirm a beneficial effect on the symptom of angina. An improvement in the Seattle angina questionnaire only approached significance and patients were not required to complete symptom diaries. Furthermore, the protocol precluded an analysis of angina threshold, since treadmill tests were terminated at the onset of 1 mm ST segment depression. Although the study was single blind in design, ECG data were recorded with the Marquette 002E software package effectively eliminating observer bias.

Conclusions
This study gives further supportive evidence of the anti-ischaemic and anti-inflammatory effect of testosterone. In the past 30 years, at least six studies of various design have reported the effects of androgen therapy on coronary ischaemia; all but one have reported a beneficial effect. The present study of exclusively hypogonadal men found the improvement in time to ischaemic threshold to be greater than that among the randomly selected men reported by English and colleagues, using identical assessment. Furthermore, the effects in the present study were seen in the presence of concomitant antianginal medications, whereas in some earlier studies angina medications were withdrawn. Major improvements in mood were reported by all patients and hypogonadal symptoms were abolished in three. The dose of testosterone used in the study may have been inadequate for some of our patients and titration of dose may be required to abolish hypogonadal symptoms in the remainder. Finally, potentially beneficial reductions in total cholesterol and reductions of TNFα were seen on testosterone treatment. There were no serious adverse effects other than a small rise in PSA, which was expected in this hypogonadal cohort. The overall level of patient satisfaction was high. Despite the limitations discussed above, this study suggests that the cautionary advice of the British National Formulary on androgen therapy may be unwarranted. Testosterone therapy offers clinical benefit to this patient group.

ACKNOWLEDGEMENTS
The authors acknowledge Miss Joanne Hall for her expert assistance with hormone ELISAs. Thanks also to Mrs Judith Edwards, Miss Lucy Gomersall, and Mrs Carole Evans for their assistance with patients during treadmill exercise testing and expertise with the Marquette 002E software package.

CJM recruited all the subjects, supervised assessment, performed statistical analysis, and wrote the paper. KK performed cytokine ELISAs; PJP and PDM helped to design the protocol and prepared the ethics submission; THJ, RDJ, and KSC evolved the concept, designed the protocol, and edited the manuscript; KSC obtained funding for the study; the guarantors of the paper are KSC and THJ.

Authors’ affiliations
C J Malkin, P J Pugh, P D Morris, K S Channer, Department of Cardiology, Royal Hallamshire Hospital, Sheffield S10 2JF, UK
K E Kerry, R D Jones, T Hugh Jones*, Academic Unit of Endocrinology, Hormone and Vascular Biology Group, Division of Genomic Medicine, University of Sheffield, Sheffield, UK
*Also the Centre for Diabetes & Endocrinology, Barnsley District General Hospital, Barnsley, UK

There is no conflict of interest
REFERENCES

www.heartjournal.co.uk
Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life

C J Malkin, P J Pugh, P D Morris, K E Kerry, R D Jones, T H Jones and K S Channer

Heart 2004 90: 871-876
doi: 10.1136/hrt.2003.021121